PixarBio Corporation (PXRB)
Stock analysis · OTC · Consumer Cyclical · Personal Products & Services
PixarBio Corporation (PXRB) is a publicly traded company in the Consumer Cyclical sector. Latest price: $0.00. Market cap $82.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Proprietary Signals
About PixarBio Corporation
PixarBio Corporation operates as a specialized pharmaceutical and biotechnology firm, primarily dedicated to the pre-clinical and clinical advancement of neurological drug delivery systems. Initially, their focus is on alleviating post-surgical pain. Beyond this, the company's extensive research and development initiatives encompass crafting innovative delivery platforms for a variety of pharmaceuticals, medical devices, or biological therapies. These systems are designed to address a broader spectrum of medical conditions, including general pain syndromes, epilepsy, Parkinson's disease, and injuries to the spinal cord. The flagship offering is the NeuroRelease platform, engineered to facilitate the controlled release of non-opioid medications. This technology is currently being assessed in pre-clinical settings for its potential in managing post-operative, acute, and persistent pain. Established in 2014, PixarBio Corporation maintains its corporate headquarters in Medford, Massachusetts.
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap